DLBCL is the most prevalent type of aggressive lymphoma in adults with Mean age of diagnosis between 45 and 65 yearsand accounts for 40% of NHL in favor for men by 1.5-3.5:1.The cause of DLBCL in most individuals is unknown, although there are related risk factors such as herbicides, pesticides, ultraviolet exposure, hair dyes and immunosuppression.
Though Notch-2 gene mutations are more uncommon, they are likely biologically significant in DLBCL and it is believed that 4.3 - 8% of cases of DLBCL have mutations in Notch-2 gene.
The therapeutic options for DLBCL in adult patients vary from standard chemotherapy to targeted therapies and bone marrow transplantation.
Aim of the work
The aim of the present study was to determine the diagnostic and prognostic implications of Notch-2 gene in DLBCL patients compared to its mutational status in healthy individuals.
PATIENTS AND METHODS:
This prospective study was conducted on 20 newly diagnosed cases of DLBCL patients and 10 healthy as control (Egyptians) in Hematology Unit at Alexandria Main University Hospital and clinics.Patients and controls were matched in the demographic criteria in the form of age (18 –59 years) and sex.The study was approved by the local Institutional Review Board, and informed consent was obtained from all study participants. Detailed clinical history and physical examination wereobtained, and samples were taken for investigations from every participant. The Notch-2 mutational status was evaluated by Sanger Sequencing Analysis.